Pharmacotherapy of addictions (original) (raw)

• Dole, V. P., Nyswander, M. E. & Kreek, M. J. Narcotic blockade. Arch. Intern. Med. 118, 304–309 (1966).The first report of research leading to the use of methadone in maintenance treatment. These initial rigorous studies document 'blockade' of the effects of the short-acting opiate heroin by the long-acting opioid methadone through the mechanism of cross-tolerance, and propose the fundamental hypothesis that addiction is a disease and not simply a criminal behaviour or personality disorder.
  Article CAS PubMed Google Scholar
• Kreek, M. J. in Improving Drug Abuse Treatment: National Institute of Drug Abuse Research Monograph Series 106 (eds Pickens, R., Leukefeld, C. & Schuster, C. R.) 245–266 (US Govt Print. Off., Washington, DC, 1991).
  Google Scholar
• Kreek, M. J. in Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (eds Schuster, C. R. & Kuhar, M. J.) 487–562 (Springer–Verlag, Berlin, 1996).
  Book Google Scholar
• Kreek, M. J. in Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (eds Schuster, C. R. & Kuhar, M. J.) 563–598 (Springer–Verlag, Berlin, 1996).
  Book Google Scholar
• Kreek, M. J. Opiates, opioids and addiction. Mol. Psych. 1, 232–254 (1996).
  CAS Google Scholar
• Kreek, M. J. Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. J. Neurochem. Res. 21, 1469–1488 (1996).
  Article CAS Google Scholar
• Kreek, M. J. in Problems of Drug Dependence, 1999; Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series Pub. No. (ADM) 00-4737,180 (ed. Harris, L. S.) 3–22 (US Govt Print. Off., Washington, DC, 2000).
  Google Scholar
• Kreek, M. J. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and the future in mainstream medicine. Ann. NY Acad. Sci. 909, 186–216 (2000).
  Article CAS PubMed Google Scholar
• Meltzer, H. Y. (ed.) Psychopharmacology: The Third Generation of Progress (New York, Raven Press, 1987).
  Google Scholar
• Davis, K. L. (ed.) Psychopharmacology: The Fifth Generation of Progress (Lippincott Williams and Wilkins, Philadelphia) (in the press).
• Kreek, M. J. & Koob, G. F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51, 23–47 (1998).One of the most rigorous of the recent reviews, including laboratory-based and human studies on the effects of drugs of abuse on the stress-responsive system, resulting in dysregulation of both the HPA axis and possibly other portions of the brain. Also rearticulates the hypothesis that an atypical responsivity to stress and stressors might contribute to the acquisition of and relapse to addictions, as has been shown in animal models after chronic self-administration.
  Article CAS PubMed Google Scholar
• Weiss, F. et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann. NY Acad. Sci. 937, 1–26 (2001).
  Article CAS PubMed Google Scholar
• Hyman, S. E. & Malenka, R. C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature Rev. Neurosci. 2, 695–703 (2001).
  Article CAS Google Scholar
• Nestler, E. J. Molecular basis of long-term plasticity underlying addiction. Nature Rev. Neurosci. 2, 119–128 (2001).
  Article CAS Google Scholar
• Weiss, F. & Porrino, L. J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J. Neurosci. 22, 3332–3337 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, S. W. & North, R. A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12, 483–488 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Ritz, M. C., Lamb, R. J., Goldberg, S. R. & Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219–1223 (1987).
  Article CAS PubMed Google Scholar
• Rocha, B. A. et al. Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci. 1, 132–137 (1998).
  Article CAS PubMed Google Scholar
• Sora, I. et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl Acad. Sci. USA 95, 7699–7704 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Sora, I. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl Acad. Sci. USA 98, 5300–5305 (2001).The first report to document the lack of cocaine reward in animals in which both the dopamine transporter and the serotonin transporter have been genetically deleted; earlier studies had shown that deletion of the dopamine or the serotonin transporter alone failed to prevent cocaine self-administration or reward.
  Article CAS PubMed PubMed Central Google Scholar
• Matthes, H. W. D. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383, 819–823 (1996).The first paper after the cloning of the μ-opioid receptor and successful gene deletion of that receptor that documented loss of μ-opioid-receptor analgesia and withdrawal symptoms after chronic opioid treatment, but also loss of reward.
  Article CAS PubMed Google Scholar
• Becker, A. et al. Morphine self-administration in μ-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 361, 584–590 (2000).
  Article CAS PubMed Google Scholar
• Sora, I. et al. Opiate receptor knockout mice define μ-receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl Acad. Sci. USA 94, 1544–1549 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Pettit, H. O., Ettenberg, A., Bloom, F. E. & Koob, G. F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacol. 84, 167–173 (1984).
  Article CAS Google Scholar
• Roberts, A. J. et al. μ-Opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 293, 1002–1008 (2000).
  CAS PubMed Google Scholar
• Roberts, A. J. et al. Increased ethanol self-administration in δ-opioid receptor knockout mice. Alcohol Clin. Exp. Res. 25, 1249–1256 (2001).
  CAS PubMed Google Scholar
• Becker, A. et al. Rewarding effects of ethanol and cocaine in μ-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 365, 296–302 (2002).The first paper to show that the rewarding effects of cocaine are significantly attenuated in the absence of an intact μ-opioid receptor; further confirmation that the μ-opioid receptor significantly reduces the rewarding effects of ethanol was also provided.
  Article CAS PubMed Google Scholar
• Hurd, Y. L., Brown, E. E., Finlay, J. M., Fibiger, H. C. & Gerfen, C. R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res. Mol. Brain Res. 13, 165–170 (1992).
  Article CAS PubMed Google Scholar
• Spangler, R., Unterwald, E. M. & Kreek, M. J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res. Mol. Brain Res. 19, 323–327 (1993).
  Article CAS PubMed Google Scholar
• Daunais, J. B., Roberts, D. C. & McGinty, J. F. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4, 543–546 (1993).
  Article CAS PubMed Google Scholar
• Unterwald, E. M., Rubenfeld, J. M. & Kreek, M. J. Repeated cocaine administration upregulates κ and μ, but not δ, opioid receptors. NeuroReport 5,1613–1616 (1994).
  Article CAS PubMed Google Scholar
• Unterwald, E. M., Kreek, M. J. & Cuntapay, M. The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res. 900, 103–109 (2001).
  Article CAS PubMed Google Scholar
• Spangler, R. et al. Prodynorphin, proenkephalin and κ-opioid receptor mRNA responses to acute 'binge' cocaine. Mol. Brain Res. 44, 139–142 (1997).
  Article CAS PubMed Google Scholar
• Wang, X. M. et al. Acute intermittent morphine increases preprodynorphin and κ-opioid receptor mRNA levels in the rat brain. Mol. Brain Res. 66, 184–187 (1999).
  Article CAS PubMed Google Scholar
• Claye, L. H., Maisonneuve, I. M., Yu, J., Ho, A. & Kreek, M. J. Local perfusion of dynorphin A 1–17 reduces extracellular dopamine levels in the nucleus accumbens. NIDA Res. Monogr. 174, 113 (1997).
  Google Scholar
• Zimprich, A. et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. 74, 472–477 (2000).
  Article CAS PubMed Google Scholar
• Chen, A. C. H. et al. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. 114, 429–435 (2002).
  Article PubMed PubMed Central Google Scholar
• Swanson, C. J, Baker, D. A., Carson, D., Worley, P. F. & Kalivas, P. W. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. Neuroscience 21, 9043–9052 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Cornish, J. L. & Kalivas, P. W. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J. Addict. Dis. 20, 43–54 (2001).This paper reviews the state of our knowledge about how the greatly differing effects of dopamine (covered in this review) and glutamate (not covered extensively in this review, but probably another major target for medication development in the near future) are involved in diverse cocaine effects that contribute to addiction and relapse.
  Article CAS PubMed Google Scholar
• McFarland, K. & Kalivas, P. W. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J. Neuroscience 21, 8655–8663 (2001).
  Article CAS Google Scholar
• Paul, M., Dewey, S. L., Gardner, E. L., Brodie, J. D. & Ashby, C. R. Jr. γ-Vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse 41, 219–220 (2001).
  Article CAS PubMed Google Scholar
• Gerasimov, M. R. et al. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur. J. Pharmacol. 414, 205–209 (2001).
  Article CAS PubMed Google Scholar
• Gerasimov, M. R. et al. γ-Vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 34, 11–19 (1999).
  Article CAS PubMed Google Scholar
• Roberts, D. C., Andrews, M. M. & Vickers, G. J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacol. 15, 417–423 (1996).
  Article CAS Google Scholar
• Shoaib, M., Swanner, L. S., Beyer, C. E., Goldberg, S. R. & Schindler, C. W. The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav. Pharmacol. 9, 195–206 (1998)
  CAS PubMed Google Scholar
• Ling, W., Shoptaw, S. & Majewska, D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Letter to the editor. Neuropsychopharmacol. 18, 403–404 (1998).
  Article CAS Google Scholar
• Kreek, M. J. Medical safety and side effects of methadone in tolerant individuals. JAMA 223, 665–668 (1973).
  Article CAS PubMed Google Scholar
• Kreek, M. J. in Neuropsychopharmacology: The Fifth Generation of Progress (ed. Davis, K. L.) 1491–1506 (Lippincott Williams and Wilkins, Philadelphia, 2002).
  Google Scholar
• Mathieu-Kia, A. M., Kellogg, S. H., Butelman, E. R. & Kreek, M. J. Nicotine addiction: insights from recent animal studies. Psychopharmacol. 162, 102–118 (2002).
  Article CAS Google Scholar
• Dole, V. P. & Nyswander, M. E. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193, 646 (1965).
  Article CAS PubMed Google Scholar
• Rettig, R. A. & Yarmolinsky, A. (eds) Federal Regulation of Methadone Treatment (National Academy Press, Washington DC,1995).
  Google Scholar
• Kreek, M. J. & Vocci, F. J. The efficacy of methadone and levomethadyl acetate (LAAM). J. Subst. Abuse Treat. (in the press).
• McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E. & O'Brien, C. P. The effects of psychosocial services in substance treatment. JAMA 269, 1953–1959 (1993).
  Article CAS PubMed Google Scholar
• Selley, D. E., Liu, Q. & Childers, S. R. Signal transduction correlates of μ-opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 285, 496–505 (1998).
  CAS PubMed Google Scholar
• Gorman, A. L., Elliott, K. J. & Inturrisi, C. E. The d and _l_-isomers of methadone bind to the non-competitive site on the _N-_methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223, 1–4 (1997).
  Article Google Scholar
• Davis, A. M. & Inturrisi, C. E. d-Methadone blocks morphine tolerance and _N_-methyl-d-aspartate (NMDA)-induced hyperalgesia. J. Pharmacol. Exp. Ther. 289, 1048–1053 (1999).
  CAS PubMed Google Scholar
• Keith, D. E. et al. μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53, 377–384 (1998).
  Article CAS PubMed Google Scholar
• Yu, Y. et al. μ-Opioid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem. 272, 28869–28874 (1997).
  Article CAS PubMed Google Scholar
• Altshuler, H. L. Behavioral methods for the assessment of alcohol tolerance and dependence. Drug Alcohol Depend. 4, 333–346 (1979).
  Article CAS PubMed Google Scholar
• Volpicelli, J. R., Alterman, A. I., Hayahida, M. & O'Brien, C. P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49, 879–880 (1992).The first paper to report the effective use of naltrexone for the treatment of alcohol dependence; a second study reported at the same time (reference 61 ) immediately confirmed and extended the documentation of the effectiveness of naltrexone, particularly when coupled with behavioral treatment, for the treatment of alcohol dependency.
  Article Google Scholar
• O'Malley, S. S. et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry 49, 881 (1992).
  Article CAS PubMed Google Scholar
• Mason, B. J. et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCI for alcohol dependence. Alcohol Clin. Exp. Res. 18, 1162–1167 (1994).
  Article CAS PubMed Google Scholar
• O'Malley, S. S., Croop, R. S., Wroblewski, J. M., Labriola, D. F. & Volpicelli, J. R. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr. Ann. 25, 681–688 (1995).
  Article Google Scholar
• Doty, P. & de Wit, H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav. Pharmacol. 6, 386–394 (1995).
  Article CAS PubMed Google Scholar
• Volpicelli, J. R., Rhines, K. C., Volpicelli, L. A., Alterman, A. I. & O'Brien, C. P. Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry 54, 737–742 (1997).
  Article CAS PubMed Google Scholar
• Mason, B. J., Salvato, F. R., Williams, L. C., Ritvo, E. C. & Cutler, R. B. A double-blind placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 56, 719–724 (1999).
  Article CAS PubMed Google Scholar
• King, A. C., Batel, P. & Kreek, M. J. Recent alcoholism treatment research: ethical issues of implementation into clinical practice. Adv. Bioethics 3, 257–286 (1997).
  Google Scholar
• King, A. C. et al. Hypothalamic–pituitary–adrenocortical (HPA) axis response and biotransformation of oral naltrexone: Preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacol. 26, 778–788 (2002).
  Article CAS Google Scholar
• O'Malley, S. S., Krishnan-Sarin, S., Farren, C., Sinha, R. & Kreek, M. J. Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamo–pituitary–adrenocortical axis. Psychopharmacol. 160, 19–29 (2002).The first paper in which the mechanism of action of opioid-receptor antagonists (including naltrexone) in the successful management of some alcohol-dependent subjects is discussed. It reports that opioid-receptor antagonists not only block the rewarding effects of endogenous opioids, but also modestly activate the HPA axis, which some scientists have proposed is part of the 'reward' that is sought by alcoholics (and cocaine addicts).
  Article CAS Google Scholar
• Bond, C. et al. Single nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608–9613 (1998).The first paper in which both differences in binding and differences in a key signal-transduction pathway are shown when ß-endorphin binds to the most common polymorphic variant of the μ-opioid receptor (caused by the A118G polymorphism). It is proposed that the presence of A118G could lead to alterations of normal physiological responses, including the stress response. In addition, this paper was the second to report the existence of this polymorphism, as well as the second most common polymorphism, C17T, and the first to report the high allelic frequency of each of these polymorphisms in diverse populations.
  Article CAS PubMed PubMed Central Google Scholar
• LaForge, K. S., Yuferov, V. & Kreek, M. J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 410, 249–268 (2000).
  Article CAS PubMed Google Scholar
• LaForge, K. S. et al. Symposium XIII: allelic polymorphisms of human opioid receptors: functional studies: genetic contributions to protection from, or vulnerability to, addictive diseases. NIDA Res. Monograph. 180, 47–50 (2000).
  Google Scholar
• Wand, G. S. et al. The μ-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacol. 26, 106–114 (2002).
  Article CAS Google Scholar
• Kampman, K. M. et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol. Depend. 63, 69–78 (2001).
  Article CAS PubMed Google Scholar
• Major, L. F., Ballenger, J. C., Goodwin, F. K. & Brown, G. L. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol. Psychiatry 12, 635–642 (1977).
  CAS PubMed Google Scholar
• Musacchio, J. M., Goldstein, M., Anagnoste, B., Poch, G. & Kopin, I. J. Inhibition of dopamine-heta-hydroxylase by disulfiram in vivo. J. Pharmacol. Exp. Ther. 152, 56–61 (1966).
  CAS PubMed Google Scholar
• McCance-Katx, E. F., Kosten, T. R. & Jatlow, P. Disulfiram effects on acute cocaine administration. Drug Alcohol. Depend. 52, 27–39 (1998).
  Article Google Scholar
• George, T. P. et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry 47, 1080–1086 (2000).
  Article CAS PubMed Google Scholar
• Carroll, K. M. et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95, 1335–1349 (2000).
  Article CAS PubMed Google Scholar
• Petrakis, I. L. et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95, 219–228 (2000).
  Article CAS PubMed Google Scholar
• Littleton, J. Acamprosate in alcohol dependence: how does it work? Addiction 90, 1179–1188 (1995).
  Article CAS PubMed Google Scholar
• Verbank, P. M. The pharmacological treatment of alcoholism: from basic science to clinical medicine. Alcohol Alcohol. 30, 757–764 (1995).
  Google Scholar
• Paille, F. M. et al. Double-blind randomized mulitcentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 30, 239–247 (1995).
  CAS PubMed Google Scholar
• Batel, P. The treatment of alcoholism in France. Drug Alcohol Depend. 39, S15–S21 (1995).
  Article CAS PubMed Google Scholar
• Chick, J. Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol. 30, 785–787 (1995).
  CAS PubMed Google Scholar
• Whitworth, A. B. et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347, 1438–1442 (1996).
  Article CAS PubMed Google Scholar
• Sass, H., Soyka, M., Mann, K. & Zieglgansberger, W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Pscyhiatry 53, 673–680 (1996).
  Article CAS Google Scholar
• Comer, S. D. et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Pyschopharmacol. 159, 351–360 (2002).
  Article CAS Google Scholar
• Kling, M. A. et al. Opioid receptor imaging with PET and [18F]cyclofoxy in long-term methadone-treated former heroin addicts. J. Pharmacol. Exp. Ther. 295, 1070–1076 (2000).
  CAS PubMed Google Scholar
• Schluger, J. H. et al. Nalmefene causes greater hypothalamic–pituitary–adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 22, 1430–1436 (1998).
  Article CAS PubMed Google Scholar
• Borg, L., Broe, D. M., Ho, A. & Kreek, M. J. Cocaine abuse sharply reduced in an effective methadone maintenance program. J. Addict. Dis. 18, 63–75 (1999).
  Article CAS PubMed Google Scholar
• Unterwald, E. M., Horne-King, J. & Kreek, M. J. Chronic cocaine alters brain μ-opioid receptors. Brain Res. 584, 314–318 (1992).The first paper in which it was unequivocally documented that chronic binge-pattern cocaine significantly alters the endogenous opioid system of the brain, including, in this case, enhancement of μ-opioid-receptor density in brain regions that have abundant dopaminergic terminals from the nigrostriatal system, as well as the mesolimbic–mesocortical dopaminergic system. This finding was later replicated in human imaging studies with increased μ-opioid-receptor binding in chronic cocaine-dependent men (reference 93).
  Article CAS PubMed Google Scholar
• Zubieta, J. K. et al. Increased μ-opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Med. 2, 1225–1229 (1996).
  Article CAS PubMed Google Scholar
• Azaryan, A. V., Clock, B. J. & Cox, B. M. Transient upregulation of μ-opioid receptor mRNA in nucleus accumbens during chronic cocaine administration. FASEB J. 10, A448 (1996).
  Google Scholar
• Yuferov, V. et al. Acute 'binge' cocaine increases μ-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system. Brain Res. Bull. 48, 109–112 (1999).
  Article CAS PubMed Google Scholar
• Kreek, M. J. et al. Circadian rhythms and levels of β-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33, 409–411 (1983).
  Article CAS PubMed Google Scholar
• Kreek, M. J. et al. ACTH, cortisol and β-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5, 277–278 (1984).
  Article CAS PubMed Google Scholar
• Schluger, J., Bodner, G., Gunduz, M., Ho, A. & Kreek, M. J. in Problems of Drug Dependence, 1997; Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series (ed. Harris, L. S.) DHHS Pub. No. ADM 98-4305, 178:105 (US Govt Print. Off., Washington DC, 1998).
  Google Scholar
• Schluger, J. H., Borg, L., Ho, A. & Kreek, M. J. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacol. 24, 568–575 (2001).The first paper in which unequivocal 'relative endorphin deficiency' was documented with atypical stress responsivity after challenge with metyrapone, which shuts off the normal tonic inhibition by cortisol of the stress-responsive HPA axis, leaving the endogenous opioids to carry out their role in inhibition. Earlier findings of the normalization of stress responsivity in long-term, methadone-maintained former heroin addicts are also confirmed.
  Article CAS Google Scholar
• Kreek, M. J. Opiate and cocaine addictions: challenge for pharmacotherapies. Pharm. Biochem. Behav. 57, 551–569 (1997).
  Article CAS Google Scholar
• Kreek, M. J. in Proc. Fourth National Conference on Methadone Treatment. National Association for the Prevention of Addiction to Narcotics (NAPAN)-NIMH 171–174 (1972).
  Google Scholar
• Kreek, M. J. Medical complications in methadone patients. Ann. NY Acad. Sci. 311, 110–134 (1978).
  Article CAS PubMed Google Scholar
• Zhou, Y. et al. Hypothalamic–pituitary–adrenal activity and POMC mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J. Endocrinol. 154, 261–267 (1999).
  Article Google Scholar
• Zhou, Y. et al. Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during 'binge' pattern cocaine administration and chronic withdrawal. J. Pharmacol. Exp. Ther. 279, 351–358 (1996).
  CAS PubMed Google Scholar
• Zhou, Y. et al. Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily 'binge' intragastric alcohol administration. Alcohol. Clin. Exp. Res. 24, 1575–1582 (2000).
  CAS PubMed Google Scholar
• Zhou, Y. et al. Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur. J. Pharmacol. 315, 31–35 (1996).
  Article CAS PubMed Google Scholar
• Spangler, R., Zhou, Y., Schlussman, S. D., Ho, A. & Kreek, M. J. Behavioral stereotypies induced by 'binge' cocaine administration are independent of drug-induced increases in corticosterone levels. Behav. Brain Res. 86, 201–204 (1997).
  Article CAS PubMed Google Scholar
• Zhou, Y. et al. Effects of chronic 'binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32. Neuroendocrinology 70, 196–199 (1999).
  Article CAS PubMed Google Scholar
• Zhou, Y., Spangler, R., Ho, A. & Kreek, M. J. Hypothalamic CRH mRNA levels are differentially modulated by repeated 'binge' cocaine with or without D1 dopamine receptor blockade. Mol. Brain Res. 94, 112–118 (2001).
  Article CAS PubMed Google Scholar
• Mendelson, J. H. et al. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropharmacol. 18, 263–271 (1998).
  CAS Google Scholar
• Kennedy, J. A., Hartman, N., Sbriglio, R., Khuri, E. & Kreek, M. J. Metyrapone-induced withdrawal symptoms. Br. J. Addict. 85, 1133–1140 (1990).
  Article CAS PubMed Google Scholar
• Culpepper-Morgan, J. A. et al. Treatment of opioid induced constipation with oral naloxone: a pilot study. Clin. Pharm. Ther. 23, 90–95 (1992).
  Article Google Scholar
• Culpepper-Morgan, J. A. & Kreek, M. J. HPA axis hypersensitivity to naloxone in opioid dependence: a case of naloxone induced withdrawal. Metabolism 46, 130–134 (1997).
  Article CAS PubMed Google Scholar
• Rosen, M. I. et al. Reliability of sequential naloxone challenge tests. Am. J. Drug Alcohol Abuse 214, 453–467 (1995).
  Article Google Scholar
• Volavka, J. et al. Naloxone increases ACTH and cortisol in man. N. Engl. J. Med. 300, 1056–1057 (1979).
  CAS PubMed Google Scholar
• Cohen, M. R., Cohen, R. M., Pickar, D., Weingartner, H. & Murphy, D. L. High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch. Gen. Psychiat. 40, 613–619 (1983).
  Article CAS PubMed Google Scholar
• Kreek, M. J., Schneider, B. S., Raghunath, J. & Plevy, S. in Abstracts of the Seventh International Congress of Endocrinology, Excerpta Medica. Int. Congress Series 652 848 (Oxford–Princeton, Amsterdam, 1984).
  Google Scholar
• Kosten, T. R., Kreek, M. J., Raghunath, J. & Kleber, H. D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol. Psychiatry 21, 217–220 (1986).
  Article CAS PubMed Google Scholar
• Kosten, T. R., Kreek, M. J., Raghunath, J. & Kleber, H. D. A preliminary study of β-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci. 39, 55–59 (1986).
  Article CAS PubMed Google Scholar
• Kosten, T. R., Morgan, C. & Kreek, M. J. β-Endorphin levels during heroin, methadone, buprenorphine and naloxone challenges: preliminary findings. Biol. Psychiatry 32, 523–528 (1992).
  Article CAS PubMed Google Scholar
• Sillaber, I. et al. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CHR1 receptors. Science 296, 931–933 (2002).
  Article CAS PubMed Google Scholar
• Di Chiara, G. & Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274–5278 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Spanagel, R., Herz, A. & Shippenberg, T. S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl Acad. Sci. USA 89, 2046–2050 (1992).The second study to clearly show the opposing role of active endogenous opioid systems in modulating the mesolimbic dopaminergic pathway (see also reference 154 ), and to show that these opposing systems are tonically active.
  Article CAS PubMed PubMed Central Google Scholar
• Metzger, R. R., Hanson, G. R., Gibb, J. W. & Fleckenstein, A. E. 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur. J. Pharmacol. 349, 205–210 (1998).
  Article CAS PubMed Google Scholar
• Bozarth, M. A. & Wise, R. A. Neural substrates of opiate reinforcement. Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 569–575 (1983).One of the earliest papers to describe the main role of dopamine, as well as numerous other neurotransmitter systems, as the neural substrate of cocaine reinforcement. This was subsequently built on in studies by many groups of the apparently central role of dopaminergic function in the reinforcing properties and other effects of cocaine and other stimulants.
  Article CAS PubMed Google Scholar
• Rassnick, S., Pulvirenti, L. & Koob, G. F. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacol. (Berl.) 109, 92–98 (1992).
  Article CAS Google Scholar
• Negus, S. S., Mello, N. K., Lamas, X. & Mendelson, J. H. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 278, 879–890 (1996).
  CAS PubMed Google Scholar
• Sherer, M. A., Kumor, K. M. & Jaffe, J. H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 27, 117–125 (1989).
  Article CAS PubMed Google Scholar
• Ohuoha, D. C., Maxwell, J. A., Thomson, L. E., Cadet, J. L. & Rothman, R. B. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J. Subst. Abuse Treat. 14, 249–258 (1997).
  Article CAS PubMed Google Scholar
• Evans, S. M. et al. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend. 64, 271–283 (2001).
  Article CAS PubMed Google Scholar
• Haney, M., Ward, A. S., Foltin, R. W. & Fischman, M. W. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacol. (Berl.) 155, 330–337 (2001).
  Article CAS Google Scholar
• Pilla, M. et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400, 371–375 (1999).
  Article CAS PubMed Google Scholar
• Platt, D. M., Rowlett, J. K. & Spealman, R. D. Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys. Psychopharmacol. (Berl.) 157, 208–216 (2001).
  Article CAS Google Scholar
• Mutschler, N. H. & Bergman, J. Effects of chronic administration of the D(1) receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacol. (Berl.) 160, 362–370 (2002).
  Article CAS Google Scholar
• Caine, S. B., Negus, S. S., Mello, N. K. & Bergman, J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J. Pharmacol. Exp. Ther. 291, 353–360 (1999).
  CAS PubMed Google Scholar
• Ranaldi, R., Wang, Z. & Woolverton, W. L. Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend. 64, 209–217 (2001).
  Article CAS PubMed Google Scholar
• Sinnott, R. S., Mach, R. H. & Nader, M. A. Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend. 54, 97–110 (1999).
  Article CAS PubMed Google Scholar
• Malcolm, R., Hutto, B. R., Phillips, J. D. & Ballenger, J. C. Pergolide mesylate treatment of cocaine withdrawal. J. Clin. Psychiatry 52, 39–40 (1991).
  CAS PubMed Google Scholar
• Eiler, K., Schaefer, M. R., Salstrom, D. & Lowery, R. Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. Am. J. Drug Alcohol Abuse 21, 65–79 (1995).
  Article CAS PubMed Google Scholar
• Levin, F. R. et al. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am. J. Addict. 8, 120–127 (1999).
  Article CAS PubMed Google Scholar
• Haney, M., Collins, E. D., Ward, A. S., Foltin, R. W. & Fischman, M. W. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacol. (Berl.) 143, 102–110 (1999).
  Article CAS Google Scholar
• Ritz, M. C., Cone, E. J. & Kuhar, M. J. Cocaine inhibition of ligand binding at dopamine, noradrenaline and serotonin transporters: a structure-activity study. Life Sci. 46, 635–648 (1990).A key paper that builds on the much earlier initial findings of Ritz and Kuhar of the relationship between dopaminergic function and the self-administration between cocaine. This seminal report focused on one of the earliest serious considerations of function and relative structure–activity of ligand binding at dopamine, noradrenaline and serotonin receptors with respect to the inhibition of cocaine effects.
  Article CAS PubMed Google Scholar
• Kolar, A. F. et al. Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 27, 849–868 (1992).
  Article CAS PubMed Google Scholar
• Arndt, I. O., Dorozynsky, L., Woody, G. E., McLellan, A. T. & O'Brien, C. P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch. Gen. Psychiatry 49, 888–893 (1992).
  Article CAS PubMed Google Scholar
• Walsh, S. L., Preston, K. L., Sullivan, J. T., Fromme, R. & Bigelow, G. E. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin. Psychopharmacol. 14, 396–407 (1994).
  CAS PubMed Google Scholar
• Margolin, A. et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40, 125–131 (1995).
  Article CAS PubMed Google Scholar
• Nunes, E. V. et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend. 39, 185–195 (1995).
  Article CAS PubMed Google Scholar
• Levin, F. R., Evans, S. M., McDowell, D. M. & Kleber, H. D. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychiatry 59, 300–305 (1998).
  Article CAS PubMed Google Scholar
• Roache, J. D., Grabowski, J., Schmitz, J. M., Creson, D. L. & Rhoades, H. M. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J. Clin. Psychopharmacol. 20, 61–68 (2000).
  Article CAS PubMed Google Scholar
• Villemagne, V. L. et al. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. Synapse 32, 44–50 (1999).
  Article CAS PubMed Google Scholar
• Ranaldi, R., Anderson, K. G., Carroll, F. I. & Woolverton, W. L. Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine. Psychopharmacol. (Berl.) 153, 103–110 (2000).
  Article CAS Google Scholar
• Cook, C. D., Carroll, F. I. & Beardsley, P. M. RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. Eur. J. Pharmacol. 442, 93–98 (2002).
  Article CAS PubMed Google Scholar
• Wilcox, K. M. et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 43, 78–85 (2002).
  Article CAS PubMed Google Scholar
• Di Chiara, G. & Imperato, A. Opposite effects of μ and κ-opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067–1080 (1988).One of two early papers published by these authors that first showed that most drugs abused by humans increase synaptic-dopamine concentration in the mesolimbic system of freely moving rats (see also reference 122 ). This is also the first study that showed the opposite effect of μ-opioid- and κ-opioid-receptor agonists in modulating dopamine release — concepts that have been substantiated by many groups and that are central to some of the potential targets for drug discovery that are discussed here.
  CAS PubMed Google Scholar
• Spanagel, R., Herz, A. & Shippenberg, T. S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55, 1734–1740 (1990).
  Article CAS PubMed Google Scholar
• Maisonneuve, I. M., Archer, S. & Glick, S. D. U50,488, a κ-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181, 57–60 (1994).
  Article CAS PubMed Google Scholar
• Bals-Kubik, R., Ableitner, A., Herz, A. & Shippenberg, T. S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264, 489–495 (1993).
  CAS PubMed Google Scholar
• Glick, S. D., Maisonneuve, I. M., Raucci, J. & Archer, S. κ-Opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681, 147–152 (1995).
  Article CAS PubMed Google Scholar
• Emmerson, P. J., Liu, M. R., Woods, J. H. & Medzihradsky, F. Binding affinity and selectivity of opioids at μ, δ and κ receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271, 1540–1547 (1994).
  Google Scholar
• Raynor, K. et al. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharmacol. 48, 330–334 (1994).
  Google Scholar
• France, C. P. & Gerak, L. R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. Ther. 270, 992–999 (1994).
  CAS PubMed Google Scholar
• Ko, M. C., Butelman, E. R., Traynor, J. R. & Woods, J. H. Differentiation of κ-opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J. Pharmacol. Exp. Ther. 285, 518–526 (1998).
  CAS PubMed Google Scholar
• Negus, S. S., Mello, N. K., Portoghese, P. S. & Lin, C. E. Effects of κ opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282, 44–55 (1997).
  CAS PubMed Google Scholar
• Kuzmin, A. V., Gerrits, M. A. & van Ree, J. M. κ-Opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats. Eur. J. Pharmacol. 358, 197–202 (1998).
  Article CAS PubMed Google Scholar
• Portoghese, P. S., Nagase, H., Lipkowski, A. W., Larson, D. L. & Takemori, A. E. Binaltorphimine-related bivalent ligands and their κ-opioid receptor antagonist selectivity. J. Med. Chem. 31, 836–841 (1988).
  Article CAS PubMed Google Scholar
• Negus, S. S., Mello, N. K., Linsenmayer, D. C., Jones, R. C. & Portoghese, P. S. κ-Antagonist effcts of the novel κ-antagonist 5′–guanidinonaltrindole (GNTI) in an assay of schedule controlled behavior. Psychopharmacol. (in the press).
• Butelman, E. R., Negus, S. S., Ai, Y., de Costa, B. R. & Woods, J. H. κ-Opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 267, 1269–1276 (1993).
  CAS PubMed Google Scholar
• Broadbear, J. H., Negus, S. S., Butelman, E. R., de Costa, B. R. & Woods, J. H. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay. Psychopharmacol. (Berl.) 115, 311–319 (1994).
  Article CAS Google Scholar
• Neumeyer, J. L. et al. Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of _N_-substituted derivatives of morphinan. Bioorg. Med. Chem. Lett. 11, 2735–2740 (2001).
  Article CAS PubMed Google Scholar
• Toll, L. et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monog. 178, 440–466 (1997).
  CAS Google Scholar
• France, C. P., Medzihradsky, F. & Woods, J. H. Comparison of κ opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J. Pharmacol. Exp. Ther. 268, 47–58 (1994).
  CAS PubMed Google Scholar
• Dykstra, L. A. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey. J. Pharmacol. Exp. Ther. 254, 248–252 (1990).
  Google Scholar
• Archer, S., Glick, S. D. & Bidlack, J. M. Cyclazocine revisited. Neurochem. Res. 21, 1369–1373 (1996).
  Article CAS PubMed Google Scholar
• Glick, S. D., Visker, K. E. & Maisonneuve, I. M. Effects of cyclazocine on cocaine self-administration in rats. Eur. J. Pharmacol. 357, 9–14 (1998).
  Article CAS PubMed Google Scholar
• Gear, R. W. et al. The κ opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83, 339–348 (1999).
  Article CAS PubMed Google Scholar
• Walsh, S. L., Geter-Douglas, B., Strain, E. C. & Bigelow, G. E. Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 299, 147–158 (2001).
  CAS PubMed Google Scholar
• Remmers, A. E. et al. Opioid efficacy in a C6 glioma cell line stably expressing the human κ opioid receptor. J. Pharmacol. Exp. Ther. 288, 827–833 (1999).
  CAS PubMed Google Scholar
• Vivian, J. A. et al. κ-Opioid receptor effects of butorphanol in rhesus monkeys. J. Pharmacol. Exp. Ther. 290, 259–265 (1999).
  CAS PubMed Google Scholar
• Heidbreder, C. A., Goldberg, S. R. & Shippenberg, T. S. The κ-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res. 616, 335–338 (1993).
  Article CAS PubMed Google Scholar
• Shippenberg, T. S., LeFevour, A. & Heidbreder, C. κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 276, 548–554 (1996).
  Google Scholar
• Mello, N. K. & Negus, S. S. Effects of κ-opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. 286, 812–824 (1998).
  CAS PubMed Google Scholar
• Dykstra, L. A., Gmerek, D. E., Winger, G. & Woods, J. H. κ-Opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242, 413–420 (1987).
  CAS PubMed Google Scholar
• Pfeiffer, A., Brantl, V., Herz, A. & Emrich, H. M. Psychotomimesis mediated by κ opiate receptors. Science 233, 774–776 (1986).
  Article CAS PubMed Google Scholar
• Ur, E., Wright, D. M., Bouloux, P. M. & Grossman, A. The effects of spiradoline (U-62066E), a κ-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120, 781–784 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Gmerek, D. E., Dykstra, L. A. & Woods, J. H. κ-Opioids in rhesus monkeys. III. Dependence associated with chronic administration. J. Pharmacol. Exp. Ther. 242, 428–436 (1987).
  CAS PubMed Google Scholar
• Kreek, M. J., Schluger, J., Borg, L., Gunduz, M. & Ho, A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulations of dopaminergic tone in the treatment of addictions. J. Pharmacol. Exp. Ther. 288, 260–269 (1999).
  CAS PubMed Google Scholar
• King, A. C., Ho, A., Schluger, J., Borg, L. & Kreek, M. J. Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects. Drug Alcohol Depend. 54, 87–90 (1999).
  Article CAS PubMed Google Scholar
• Nakazawa, T. et al. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. J. Pharmacol. Exp. Ther. 252, 1247–1254 (1990).
  CAS PubMed Google Scholar
• Yu, J., Butelman, E. R., Woods, J. H., Chait, B. T. & Kreek, M. J. Dynorphin A (1-8) analog, E-2078, is stable in human and rhesus monkey blood. J. Pharmacol. Exp. Ther. 280, 1147–1151 (1997).
  CAS PubMed Google Scholar
• Butelman, E. R., Harris, T. J. & Kreek, M. J. Effects of E-2078, a stable dynorphin A(1–8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacol. (Berl.) 147, 73–80 (1999).The first paper to report directly the dopamine-lowering effects of a synthetic dynorphin-peptide analogue when administered to a non-human primate. This compound, which has been safely used in humans for analgesic purposes, but never completely developed for human use, is a prototype of a potential medication that might be effective for some aspects of cocaine and other stimulant dependency.
  Article CAS Google Scholar
• Ohnishi, A. et al. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J. Pharmacol. Exp. Ther. 270, 342–347 (1994).
  CAS PubMed Google Scholar
• Bergen, A. W., et al. μ-Opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2, 490–494 (1997).
  Article CAS PubMed Google Scholar
• Szeto, C. Y., Tang, N. L., Lee, D. T. & Stadlin, A. Association between μ-opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12, 1103–1106 (2001).
  Article CAS PubMed Google Scholar
• Mark, T. L., Woody, G. E., Juday, T. & Kleber, H. D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 61, 195–206 (2001).
  Article CAS PubMed Google Scholar